OMV Strain Engineering Service for Enhanced CAR-T Adjuvant Potency

Q: Q2: Is it possible to incorporate custom targeting moieties or immunomodulators onto the OMV surface?

A2: Certainly. Leveraging our flexible Plug-and-Display system, we facilitate the covalent conjugation of your specific SpyCatcher-tagged proteins, including scFvs or cytokines, onto SpyTag-functionalized OMVs during vesicle biogenesis, enabling precise and stable surface presentation.

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

While CAR-T therapy has achieved remarkable success in hematologic malignancies, its efficacy against solid tumors remains constrained by the immunosuppressive tumor microenvironment (TME), limited T-cell infiltration, and antigen escape mechanisms. To address these critical barriers, we introduce our OMV Strain Engineering for Enhanced CAR-T Adjuvant Potency service—a proprietary platform designed to transform "cold" tumors into immune-active "hot" zones. Through modular bacterial vesicle programming and precision biogenesis optimization, we engineer outer membrane vesicles (OMVs) that function as potent adjuvants to remodel the TME and synergize with CAR-T cells. This service empowers you to maximize CAR-T persistence and enhance intratumoral infiltration.

Introduction

OMV strain engineering involves the genetic manipulation of bacterial parent strains to modify the composition and surface display of cargo on their naturally secreted nanosized proteoliposomes. This approach is significant as it transforms native immunogenic vesicles into customizable and potent adjuvants, capable of precisely modulating innate immune responses to overcome the immunosuppressive tumor microenvironment. Consequently, engineered OMVs represent a promising synthetic biology platform to synergize with CAR-T cell therapy, potentially enhancing their in vivo expansion, persistence, and cytotoxic activity against solid tumors.

Fig.1 Enhancing CAR-T cell efficacy against solid tumors via engineered bacterial outer membrane vesicles. (Creative Biolabs Original) Fig.1 Engineering bacterial outer membrane vesicles as potent adjuvants for CAR-T cell therapy.

OMV Strain Engineering for Enhanced CAR-T Adjuvant Potency at Creative Biolabs

Creative Biolabs offers OMV Strain Engineering to generate customized OMV that function as potent immunoadjuvants for CAR-T therapy. By reprogramming parent bacterial strains, our OMVs remodel the immunosuppressive tumor microenvironment, enhance T-cell infiltration, and counteract exhaustion. This service empowers you to transform solid tumors into immune-permissive niches, maximizing CAR-T persistence and therapeutic efficacy.

What We Can Offer

We offer a suite of cutting-edge, engineered outer membrane vesicle (OMV) platforms designed to function as multifunctional adjuvants, systematically enhancing CAR-T cell potency by remodeling the immunosuppressive tumor microenvironment and overcoming antigen heterogeneity.

Featured services of OMV strain engineering for enhanced CAR-T adjuvant potency at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Target Profiles: Specific tumor-associated antigens (TAAs) or neoantigens for OMV surface display.
CAR-T Construct Data: Information on the costimulatory domains to ensure OMV-adjuvant compatibility.
Strain Preferences: Specific bacterial backgrounds if required for specific tissue tropism.

Key Steps:

Workflow of OMV strain engineering for enhanced CAR-T adjuvant potency at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Comprehensive Characterization Report: Detailed data on OMV size, purity, and surface protein quantification.
Purified OMV Adjuvants: Stabilized, ready-to-use engineered vesicles in requested concentrations.
Efficacy Documentation: Results from TME-remodeling assays demonstrating CAR-T activation markers.

Key Advantages

Dual-Action Synergy: Our engineered OMV platform concurrently disrupts immune checkpoints and delivers antigen tags, creating a multifunctional "adjuvant system" that directly targets the immunosuppressive TME and tumor heterogeneity.
Native Immunogenicity: Leveraging the bacterial origin of OMVs, our platform provides a natural adjuvant effect that activates innate immunity, further enhancing CAR-T cell infiltration and persistence within solid tumors.
Superior Safety Profile: By utilizing outer membrane vesicles instead of live bacteria, our approach eliminates the risk of bacterial infection while retaining potent therapeutic efficacy, ensuring a safer profile for in vivo applications.

FAQs

Q1: What safety measures are integrated to prevent off-target toxicity from OMVs?

A1: Our engineered bacterial strains feature modified Lipid A components to minimize endotoxic activity. For added precision, we offer a biomineralization strategy that encases OMVs within a pH-sensitive calcium phosphate shell, ensuring localized adjuvant release specifically within the acidic tumor microenvironment while protecting peripheral tissues.

Q2: Is it possible to incorporate custom targeting moieties or immunomodulators onto the OMV surface?

A2: Certainly. Leveraging our flexible "Plug-and-Display" system, we facilitate the covalent conjugation of your specific SpyCatcher-tagged proteins, including scFvs or cytokines, onto SpyTag-functionalized OMVs during vesicle biogenesis, enabling precise and stable surface presentation.

Why Choose Us

Choose Creative Biolabs for our unique intersection of microbiology and immunology expertise. Our modular "Plug-and-Display" platform enables multi-functional protein presentation, while proprietary detoxification mutants minimize systemic inflammation without compromising local adjuvant potency.

Customer Reviews

"Using Creative Biolabs's OMV engineering in our research has significantly facilitated the conversion of M2 macrophages to the anti-tumor M1 phenotype. The consistency in vesicle size and the ease of the SpyTag attachment system saved us months of troubleshooting." Dr. Alen*** W.

"Using the biomineralized OMV platform in our solid tumor studies has significantly improved the therapeutic window of our CAR-T therapy. We observed zero systemic cytokine storms even at doses 3x higher than our previous iterations." Prof. Sar*** K.

"Using Creative Biolabs' OMV Strain Engineering has significantly improved the metabolic fitness of our CAR-T cells. The localized delivery of metabolic modulators via OMVs prevented the usual T-cell exhaustion observed in hypoxic environments." Dr. Li*** J.

How to contact us?

Drive your OMV-CAR-T program forward with our expert strain engineering. We specialize in custom strain development and scalable production to boost your adjuvant's potency. Contact our team today to discuss your specific project needs.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.